Revenue (Tables)

9 Months Ended

Sep. 30, 2021

Revenue

Schedule of revenue recognized from collaborative arrangements

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2021		2020		2021		2020
Janssen	$	2,788	$	7,252	$	8,621	$	19,353
Other		9		9		28		28
Total collaboration revenue	$	2,797	$	7,261	$	8,649	$	19,381

Summary of profit sharing revenue and collaboration loss

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2021		2020		2021		2020
Viatris collaboration agreement - Amounts receivable from Viatris	$	10,397	$	10,996	$	31,716	$	32,246

Summary of the reductions to R&D costs related to reimbursement payments

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2021		2020		2021		2020
Janssen	$	2,205	$	1,461	$	4,730	$	4,231
Viatris		1,096		(57)		1,257		1,565
Total reduction to R&D expense, net	$	3,301	$	1,404	$	5,987	$	5,796